CheapRobot
$200 Million cash (approx.) enough?? Plus banking more cash every day, I think they have plenty of capital. If they get Vitiligo approved which seems likely IMO then there will be so much cash they will be able to fund Phase 3s for Stroke and Parkinson's assuming Phase 2s are promising. VP and XP less expensive to get market approval but will also add significantly to the cash pile and both already have ODD. Most other small biotech out licenses or other various deals with their drugs to big Pharma because they can't afford clinical programs, that's not happening here they will have to be bought out.
Vitiligo Phase 3 running, slated for FDA submission 2026, drug already FDA approved and SAFE for EPP. Vitiligo TAM mentioned $4.5 BILLION USD and 9% penetration years 1-2 giving $490 - $570 Million USD. Compelling pictures of treatment shown and lots of centres ready to go if/when approved and solid results from Phase 2. A lot of that revenue will just drop straight to the bottom line as profits IMO, there is no big Pharma to pay royalties to etc and only 50 Million CUV shares on issue.
All IMO DYOR
CheapRobot$200 Million cash (approx.) enough?? Plus banking more...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.37 |
Change
0.180(1.36%) |
Mkt cap ! $669.5M | |||
| Open | High | Low | Value | Volume |
| $13.19 | $13.59 | $13.13 | $1.181M | 88.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 606 | $13.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.51 | 282 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |